Departure of Ariad director sparks speculation that Berger's days are numbered

The departure of business adviser Robert Whelan from the board of directors at Ariad Pharmaceuticals last week is fueling speculation that CEO and co-founder Harvey Berger may soon be under pressure to step down from the struggling cancer biotech firm...